With Over 1.25 Billion Jabs in India, SII Seeks Full Approval for Covishield
With supplies of Covishield exceeding 1.25 billion doses, there is enough data for full market approval, says SII.
Published:
Serum Institute of India (SII) CEO Adar Poonawalla. Image used for representational purposes.
(Image: The Quint)
ADVERTISEMENT
Serum Institute of India (SII) chief Adar Poonawalla, on Friday, 31 December, announced that the firm had applied to the country's drug regulator and the Health Ministry for full authorisation for its COVID-19 vaccine, Covishield.
Poonawalla said that with supplies of Covishield in India exceeding 1.25 billion doses, the government of India had enough data for full market authorisation.
SII had been granted emergency approval in India for Covishield earlier this year.
(At The Quint, we are answerable only to our audience. Play an active role in shaping our journalism by becoming a member. Because the truth is worth it.)
SCROLL FOR NEXT